Understanding Clinical and Economic Impact of Compliance to GOLD Treatment Recommendations in Patients with COPD

Webinar Recorded on May 14, 2020 
Sponsored by Boehringer-Ingelheim 

Download Presentation

Chronic obstructive pulmonary disease (COPD) generates an economic and social burden that is both substantial and increasing, making for complicated decisions in managed markets.

Suboptimal adherence to COPD medication is associated with negative consequences related to disease control, mortality, and healthcare resource use, but what about adherence to treatment guidelines?

In this presentation, the primary researcher and an industry expert, who is a former payer, combine their expertise to report on real-world data supporting compliance with Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations and how it can be used to help you navigate management of your COPD population.

The presentation will examine:

• GOLD recommendations
• Current prescribing behaviors for COPD
• New real-world data supporting compliance to GOLD recommendations, including clinical and economic outcomes

This information is intended only for formulary decision makers or other similar entities making population-based decisions.

Speakers:

• Swetha Palli MS, BPharm
  Product Director Health Economics and Outcomes Research
  Boehringer Ingelheim Pharmaceuticals Inc
• Andrew Cournoyer RPh, MBA
  Vice President Director
  Access Experience Team
  PRECISIONvalue
  Former Head of Formulary and Utilization Management

This webinar is sponsored, developed and presented by the sponsor. The content of this Science & Innovation Theater Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP. 

Sponsored by: